| Similar Articles |
|---|
 |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances?   |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
Chemistry World
May 4, 2011
Andrew Turley |
Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant. |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
The Motley Fool
May 11, 2011
Jared Cummans |
Wednesday's ETF to Watch: iShares MSCI Israel Fund Teva Pharmaceuticals releases earnings today. |
The Motley Fool
May 2, 2011
Arundhati Parmar |
Teva pays $6.8B to buy Cephalon, including Minnesota's CIMA Labs Teva diversifies. |
Chemistry World
July 30, 2013
Emma Stoye |
Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb. |
The Motley Fool
March 12, 2009
Robert Steyer |
A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another. |
The Motley Fool
January 14, 2011
Christopher Barker |
Cliffs Dives Deep Into Iron Ore for Asia The miner vies to join the big leagues of export-bound iron ore production. |
The Motley Fool
July 6, 2006
Brian Lawler |
Cephalon on the Hunt The biopharma company is looking to make more acquisitions and gets some good news from the FDA. Cephalon's stock climbed by more than 10% after the announcement. |
BusinessWeek
May 5, 2011
Caroline Winter |
Bid & Ask Noteworthy expenditures of the week: DuPont upped its bid for the Danish food ingredients maker Danisco... Teva Pharmaceutical agreed to pay $6.2 billion for Cephalon... Applied Materials is buying Varian Semiconductor... more... |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
Chemistry World
November 24, 2014
Andy Extance |
Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis. |
The Motley Fool
January 15, 2008
Brian Orelli |
Fewer Generics in Fido's Future TEVA considers selling its small animal-health business. |
The Motley Fool
October 5, 2011
Dan Caplinger |
Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future. |
The Motley Fool
July 25, 2005
Stephen D. Simpson |
Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
AFP eWire
April 21, 2008 |
Revenue Growth, Donors Continue to Decline Charitable organizations participating in the Target Analytics Index of National Fundraising Performance experienced negative revenues from 2006 to 2007 and continued to see declines in the number of donors. |
The Motley Fool
February 16, 2007
Brian Lawler |
Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note. |
The Motley Fool
June 10, 2011
Matt Koppenheffer |
5 Companies Ready to Make Acquisitions Could corporate deal-making help drive the market in the second half of the year? |
The Motley Fool
December 17, 2011
Matt Koppenheffer |
This Week's Top Stock Gainers It wasn't a great week for the market, but some stocks and sectors were able to come out of it ahead of the rest. |
The Motley Fool
September 30, 2011
Brian Orelli |
When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs. |
Pharmaceutical Executive
November 1, 2005
Sara Calabro |
Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles. |
The Motley Fool
February 17, 2010
Brian Orelli |
This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it. |
The Motley Fool
June 10, 2011
Matt Koppenheffer |
Could Teva Pharmaceutical Score You 100% Returns? Is it high time to add Teva's stock to your portfolio? |
The Motley Fool
June 28, 2011
Eric Bleeker |
Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
